Karyopharm Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.33 | -$0.33 | -$0.33 |
| Q2 2024 | 3 | -$0.30 | -$0.30 | -$0.30 |
| Q3 2024 | 5 | -$0.33 | -$0.17 | -$0.26 |
| Q4 2024 | 3 | -$0.24 | -$0.24 | -$0.24 |
| Q1 2025 | 4 | -$0.16 | -$0.16 | -$0.16 |
| Q2 2025 | 4 | -$0.14 | -$0.14 | -$0.14 |
| Q3 2025 | 4 | -$0.16 | -$0.16 | -$0.16 |
| Q4 2025 | 4 | -$0.16 | -$0.16 | -$0.16 |
Karyopharm Therapeutics Inc. Earnings Date And Information
Karyopharm Therapeutics Inc. last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.2 earnings per share for the quarter, topping analysts' consensus estimates of $-0.29 by $0.09. The company had revenue of 42.79 M for the quarter and had revenue of 146.03 M for the year. Karyopharm Therapeutics Inc. has generated $-1 earnings per share over the last year ($-1.25 diluted earnings per share) and currently has a price-to-earnings ratio of -1.14. Karyopharm Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based on prior year's report dates.
Karyopharm Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/06/2024 | Q2 2024 | -$0.29 | $0.20 | 0.49 | $36.21 M | $42.79 M |
| 05/08/2024 | Q1 2024 | -$0.33 | -$0.32 | 0.01 | $33.13 M | |
| 02/29/2024 | Q4 2023 | -$0.29 | -$0.36 | -0.07 | $33.75 M | |
| 11/02/2023 | Q3 2023 | -$0.28 | -$0.30 | -0.02 | $37.27 M | $36.01 M |
| 08/02/2023 | Q2 2023 | -$0.34 | -$0.29 | 0.05 | $35.67 M | $37.58 M |
| 05/04/2023 | Q1 2023 | -$0.34 | -$0.30 | 0.04 | $38.70 M | |
| 02/17/2023 | Q4 2022 | -$0.43 | $33.58 M | |||
| 11/03/2022 | Q3 2022 | -$0.56 | -$0.45 | 0.11 | $34.83 M | $36.15 M |
| 08/04/2022 | Q2 2022 | -$0.63 | -$0.62 | 0.01 | $35.96 M | $39.68 M |
| 05/05/2022 | Q1 2022 | -$0.63 | -$0.53 | 0.1 | $47.67 M | |
| 03/01/2022 | Q4 2021 | $0.51 | $126.27 M | |||
| 11/03/2021 | Q3 2021 | -$0.68 | -$0.69 | -0.01 | $26.21 M | $37.69 M |
| 08/05/2021 | Q2 2021 | -$0.72 | -$0.71 | 0.01 | $26.30 M | $22.60 M |
| 05/04/2021 | Q1 2021 | -$0.77 | $23.26 M | |||
| 02/24/2021 | Q4 2020 | -$0.59 | $35.10 M | |||
| 11/02/2020 | Q3 2020 | -$0.73 | -$0.73 | 0 | $23.02 M | $21.33 M |
| 08/04/2020 | Q2 2020 | -$0.57 | -$0.63 | -0.06 | $28.41 M | $33.51 M |
| 05/05/2020 | Q1 2020 | -$0.70 | -$0.78 | -0.08 | $18.14 M | |
| 02/26/2020 | Q4 2019 | -$0.76 | $18.10 M | |||
| 11/04/2019 | Q3 2019 | -$0.84 | -$0.67 | 0.17 | $2.77 M | $13.15 M |
Karyopharm Therapeutics Inc. Earnings: Frequently Asked Questions
-
When is Karyopharm Therapeutics Inc.'s earnings date?
Karyopharm Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates.
-
Did Karyopharm Therapeutics Inc. beat their earnings estimates last quarter?
In the previous quarter, Karyopharm Therapeutics Inc. (:KPTI) reported $-0.2 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.29 by $0.09.
-
How can I listen to Karyopharm Therapeutics Inc.'s earnings conference call?
The conference call for Karyopharm Therapeutics Inc.'s latest earnings report can be listened to online.
-
How can I read Karyopharm Therapeutics Inc.'s conference call transcript?
The conference call transcript for Karyopharm Therapeutics Inc.'s latest earnings report can be read online.
-
How much revenue does Karyopharm Therapeutics Inc. generate each year?
Karyopharm Therapeutics Inc. (:KPTI) has a recorded annual revenue of $146.03 M.
-
How much profit does Karyopharm Therapeutics Inc. generate each year?
Karyopharm Therapeutics Inc. (:KPTI) has a recorded net income of $146.03 M. Karyopharm Therapeutics Inc. has generated $-1.25 earnings per share over the last four quarters.
-
What is Karyopharm Therapeutics Inc.'s price-to-earnings ratio?
Karyopharm Therapeutics Inc. (:KPTI) has a price-to-earnings ratio of -1.14 and price/earnings-to-growth ratio is -0.03.
